Name: Tumor Board: Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum
Start: 2025-09-07T18:30:00+02:00
End: 2025-09-07T19:30:00+02:00

Regulatory Agency Perspective

September 1, 2016

NCI Corner – Interview with Dinah S. Singer, PHD

By

Regulatory Agency Perspective

By Erik J. MacLaren, PhD Blue Ribbon Panel of the US National Cancer Advisory BoardDuring his State of the Union address in January 2016, President Barack Obama announced a new […]
June 1, 2016

Small Cell Lung Cancer: The Next Challenge

By

Regulatory Agency Perspective

By Peter Ujhazy, MD, PhD The newfound optimism in the management of lung cancer that infused the research, clinical, and patient communities 12 years ago is still gaining momentum. Seminal […]

June 1, 2016

Interview with Richard Pazdur, MD

By

Regulatory Agency Perspective

New oncology drugs have, for decades, followed a well-trodden path of sequential clinical trials to get from the laboratory to the patient. This model has proven its worth by delivering […]
April 6, 2016

FDA Corner – Interview with Gideon Blumenthal, MD

By

Regulatory Agency Perspective

By Erik J. Mac Laren, PhD In 2015, the US Food and Drug Administration (FDA) approved an unprecedented 7 new drugs or new uses for drugs for patients with lung […]
April 1, 2016

NCI Corner – Interview with Shakun Malik, MD

By

Regulatory Agency Perspective

By Erik J. Mac Laren, PhD In late 2015, the US National Cancer Institute (NCI) Thoracic Malignancy Steering Committee (TMSC) published its strategic priorities for the coming years. These include: […]

Regulatory Agency Perspective

NCI Corner – Interview with Dinah S. Singer, PHD

Small Cell Lung Cancer: The Next Challenge

Interview with Richard Pazdur, MD

FDA Corner – Interview with Gideon Blumenthal, MD

NCI Corner – Interview with Shakun Malik, MD

IS03: Satellite EBAC/CME Symposium by Answers in CME: Reshaping the Management of Metastatic NSCLC: Tackling HER2 Overexpression to Elevate Outcomes

Tumor Board: Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum

COCOON’s Prophylactic Regimen Resulted in Decreased Incidence and Severity of Dermatologic-related Adverse Events

MARIPOSA OS Data Confirms Improved Efficacy for Amivantamab Plus Lazertinib in the First Line for EGFR-mutated NSCLC